← SynDRA
CALCIPOTRIENE
SynDRA canonical compound SYN0023116 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | VDR |
| Mechanism of action | vitamin D receptor agonist |
| Indication | psoriasis |
| Disease area | dermatology |
All known targets
Mechanisms of action (all sources)
- VDR AGONIST
- Vitamin D receptor agonist
- VDR ANTAGONIST
Drug classes
- Dermatologic Agents
- Vitamin D Analog
ATC classes
- D05A · ANTIPSORIATICS FOR TOPICAL USE
Cross-references
Synonyms
- calcipotriol
- calciptriol
- daivonex
- dovonex
- calcipotriene hydrate
- calcipotriol hydrate
- Calcipotriol
- Calcipotriene hydrate
- Calcipotriol hydrate
- Calcipotriene monohydrate
- Calcipotriol anhydrous
- Calcipotriol monohydrate
- Calciptriol
- MC-903
- PRI-2201
- Calcipotriene component of enstilar
- Calcipotriene component of taclonex
- Calcipotriene component of wynzora
- Calcipotriene hydrate component of taclonex
- Dovobet
- Dovonex
- Enstilar
- Sorilux
- Xamiol
- Divonex
- BMS-181161
- Daivonex (TN)
- Dovonex (TN)
- (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
- (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL
- 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
- calcipotriene (usp-rs)
- MC 903
- calcipotriene (usp monograph)
- PRI 2201
- calcipotriol (ep monograph)
- Daivonex
- Calcitrene
Reported adverse events
- Rash
- Erythema
- Burning sensation
- Skin atrophy
- Skin irritation
- Psoriasis
- Dry skin
- Folliculitis
- Headache
- Pain
- Pruritus
- Application site pruritus
Look up CALCIPOTRIENE in the interactive SynDRA portal →